Clinical relevance of reduced bioavailability of rifampicin
Bhatt, A.D.; Vaz, J.A.; Padgaonkar, K.A.
Journal of the Association of Physicians of India 46(8): 729-731
1998
ISSN/ISBN: 0004-5772 PMID: 11229285 Document Number: 490212
Bioavailability (BA) of rifampicin (RMP) is a critical factor in successful treatment of tuberculosis. The BA of RMP can be reduced by pharmaceutical factors, patient factors and drug interactions. Failure of treatment and development of drug resistance are potential consequences of reduction in BA and it is necessary to understand and control the factors influencing BA of RMP.
Document emailed within 1 workday
Related Documents
Zwolska, Z.; Augustynowicz-Kopeć, E.; Niemirowska-Mikulska, H. 2002: The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule Acta Poloniae Pharmaceutica 59(6): 448-452Breese, G.R.; Baumeister, A.A.; McCown, T.J.; Emerick, S.G.; Frye, G.D.; Crotty, K.; Mueller, R.A. 1984: Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine Journal of Pharmacology and Experimental Therapeutics 231(2): 343-354
Lindgren, B.F.; Segovia, B.; Lassarre, C.; Binoux, M.; Gourmelen, M. 1996: Growth retardation in constitutionally short children is related both to low serum levels of insulin-like growth factor-i and to its reduced bioavailability Growth Regulation 6(3): 158-164
Tamura, M.; Yamazaki, A.; Tamura, T.; Takano, S.; Yamazaki, M. 1973: The critical concentration of clinical rifampicin resistance for tubercle bacilli and the acquirement pattern of rifampicin resistance of tubercle bacilli on Kirchner's semi-liquid agar media Kekkaku: 48(6): 247-253
Medoff, G.; Kwan, C.N.; Schlessinger, D.; Kobayashi, G.S. 1973: Potentiation of rifampicin, rifampicin analogs, and tetracycline against animal cells by amphotericin B and polymyxin B Cancer Research 33(6): 1146-1149
Poupon, R.Y.; Meyniel, D.; Petit, J.; Gustot, P.; Darnis, F. 1979: Cholestatic hepatitis during treatment with I.N.H. and rifampicin: arguments in favour of the hepatotoxicity of rifampicin Annales de Medecine Interne 130(6-7): 371-375
Rossolini, A.; Cellesi, C.; Debolini, A. 1973: Experimental study of liver damage due to rifampicin and rifampicin-isoniazid combination Il Farmaco; Edizione Pratica 28(6): 345-355
Saltoglu, N.; Tasova, Y.; Inal, A.S.; Seki, T.; Aksu, H.S. 2002: Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis Saudi Medical Journal 23(8): 921-924
Panchagnula, R.; Singh, I.; Kaur, K.J.; Kaul, C.L. 1999: Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations Methods and Findings in Experimental and Clinical Pharmacology 21(9): 625-628
Acocella, G.; Segre, G. 1974: Kinetics of rifampicin and desacetyl-rifampicin in plasma, bile, and urine in humans and the effect of repeated administrations Acta Pharmaceutica Suecica 11(6): 657-658
Reimers, D. 1971: Malformations caused by rifampicin? 2 cases of normal fetal development after rifampicin treatment in early pregnancy Münchener Medizinische Wochenschrift 113(50): 1690-1691
Fafrowicz, B. 1971: Rifampicin and its clinical use Wiadomosci Lekarskie 24(3): 233-238
Firsov, A.A.; Piotrovskii, V.K. 1986: Methods for estimating drug bioavailability parameters. Part 3: Peculiarities of pharmacokinetic analysis in assessment of bioavailability Die Pharmazie 41(7): 457-465
Del Rosso, J.Q. 2013: What more can we learn about acne and rosacea? Just keep reading, questioning, and searching for clinical relevance beyond the limitations of clinical trials Journal of Drugs in Dermatology: Jdd 12(6): 609-610
1999: From the Clinical Effectiveness Committee. Use of rifampicin and contraceptive steroids British Journal of Family Planning 24(4): 169-170
Tsubota, N.; Tanimukai, S. 2015: A Clinical Experience of Rifampicin Suppository for the Treatment of Pulmonary Tuberculosis Kekkaku: 90(6): 543-547
Silva, J.; Herrera, N.; Becerra, S.; Jofré, M.; Gutiérrez, A.; Hannelore 1981: Comparative in vitro activity of aminoglycosides and rifampicin upon bacteria from clinical specimens Revista Medica de Chile 109(3): 231-235
Glasser, A.C. 1987: Aspects of bioavailability and bioequivalence revision: possible implications on clinical pharmacology Methods and Findings in Experimental and Clinical Pharmacology 9(7): 449-452
González, N.; Torres, M.J.; Palomares, J.C.; Aznar, J. 1998: Characterization of the rpoB gene mutations in clinical isolates of rifampicin-resistant Mycobacterium tuberculosis Enfermedades Infecciosas y Microbiologia Clinica 16(9): 404-407
Generozov, E.V.; Al'tshuler, M.L.; Govorun, V.M.; Lopukhin, I.M.; Golyshevskaia, V.I.; Chernousova, L.N.; Khomenko, A.G. 1999: Detection and characteristics of rpoB gene mutations in rifampicin-resistant clinical strains of M. tuberculosis Problemy Tuberkuleza 2: 39-42